A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Erasca, Inc.
- Last updated on ClinicalTrials.gov
- September 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Providence Medical Group · Santa Rosa, CA
Colorado · 1
- University of Colorado · Aurora, CO
Florida · 2
- Florida Cancer Specalists · Sarasota, FL
- Moffitt Cancer Center · Tampa, FL
Massachusetts · 1
- Massachusetts General Hospital (MG) · Boston, MA
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Texas · 2
- The University of Texas MD Anderson Cancer Center · Houston, TX
- University of Texas at Tyler · Tyler, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.